Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Five9, Inc. stock logo
FIVN
Five9
$26.60
-4.5%
$27.28
$21.04
$49.90
$2.03B1.191.78 million shs1.81 million shs
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
$22.58
-2.5%
$19.01
$14.21
$29.29
$10.09B2.1312.97 million shs10.94 million shs
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$18.03
$18.03
$5.31
$31.73
$1.42B2.323.17 million shsN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$567.74
+1.4%
$545.98
$476.49
$1,211.20
$61.30B0.33913,803 shs844,505 shs
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$175.77
+1.2%
$165.39
$109.82
$178.76
$16.33B1.641.56 million shs946,825 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Five9, Inc. stock logo
FIVN
Five9
-3.06%+0.98%-4.72%+20.76%-30.35%
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
+5.59%+5.59%+17.38%+41.96%+23.61%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.30%+2.71%+6.92%+1.01%-47.74%
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
+1.58%+1.38%+11.31%+40.55%+33.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Five9, Inc. stock logo
FIVN
Five9
4.1391 of 5 stars
4.42.00.00.03.42.51.9
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
4.6621 of 5 stars
3.42.00.01.22.41.74.4
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.8352 of 5 stars
4.43.01.72.32.51.71.9
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
4.7614 of 5 stars
2.45.00.04.33.02.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Five9, Inc. stock logo
FIVN
Five9
2.73
Moderate Buy$43.1562.22% Upside
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
2.71
Moderate Buy$25.1611.42% Upside
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00
N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.80
Moderate Buy$814.5743.48% Upside
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
2.89
Moderate Buy$184.534.98% Upside

Current Analyst Ratings Breakdown

Latest PTLA, REGN, THC, FIVN, and NCLH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$560.00 ➝ $584.00
7/11/2025
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$184.00 ➝ $194.00
7/10/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$755.00 ➝ $754.00
7/9/2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00
7/7/2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $29.00
6/30/2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$29.00 ➝ $23.00
6/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/18/2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
6/9/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.00
6/9/2025
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$175.00 ➝ $210.00
6/6/2025
Five9, Inc. stock logo
FIVN
Five9
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$35.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Five9, Inc. stock logo
FIVN
Five9
$1.04B1.95$2.02 per share13.16$8.27 per share3.22
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
$9.48B1.06$4.25 per share5.31$3.24 per share6.97
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$116.64M12.13N/AN/A$1.67 per share10.80
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.09B4.35$46.96 per share12.09$268.50 per share2.11
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$20.67B0.79$21.62 per share8.13$61.20 per share2.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Five9, Inc. stock logo
FIVN
Five9
-$12.80M-$0.09N/A35.472.74-0.48%6.06%1.79%8/6/2025 (Estimated)
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
$910.26M$1.7313.0512.340.389.05%66.78%3.84%7/30/2025 (Estimated)
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
-$290.66M-$4.06N/AN/AN/A-232.73%-267.86%-54.66%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.2814.4514.932.0631.94%15.27%11.93%8/1/2025 (Estimated)
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$3.20B$15.1211.6313.081.257.09%22.58%4.29%7/22/2025 (Confirmed)

Latest PTLA, REGN, THC, FIVN, and NCLH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.53N/AN/AN/A$3.30 billionN/A
7/30/2025Q2 2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
$0.51N/AN/AN/A$2.55 billionN/A
7/22/2025Q2 2025
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$2.84N/AN/AN/A$5.16 billionN/A
5/1/2025Q1 2025
Five9, Inc. stock logo
FIVN
Five9
$0.48$0.62+$0.14$0.01$272.26 million$279.71 million
4/30/2025Q1 2025
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
$0.09$0.07-$0.02-$0.09$2.15 billion$2.13 billion
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion
4/29/2025Q1 2025
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$3.11$4.36+$1.25$4.27$5.15 billion$5.22 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Five9, Inc. stock logo
FIVN
Five9
N/AN/AN/AN/AN/A
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
N/AN/AN/AN/AN/A
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.62%N/A8.96%N/A
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
N/AN/AN/AN/AN/A

Latest PTLA, REGN, THC, FIVN, and NCLH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%5/20/20255/20/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Five9, Inc. stock logo
FIVN
Five9
1.12
2.02
2.02
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
9.09
0.19
0.16
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
4.77
4.87
4.82
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.93
4.03
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
2.23
1.78
1.70

Institutional Ownership

CompanyInstitutional Ownership
Five9, Inc. stock logo
FIVN
Five9
96.64%
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
69.58%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
98.68%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
95.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Five9, Inc. stock logo
FIVN
Five9
3,07376.27 million75.05 millionOptionable
Norwegian Cruise Line Holdings Ltd. stock logo
NCLH
Norwegian Cruise Line
41,700446.81 million444.98 millionOptionable
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
32478.48 millionN/AOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106107.97 million100.39 millionOptionable
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
98,00092.89 million92.13 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Five9 stock logo

Five9 NASDAQ:FIVN

$26.60 -1.26 (-4.52%)
Closing price 04:00 PM Eastern
Extended Trading
$26.56 -0.04 (-0.15%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Five9, Inc., together with its subsidiaries, provides intelligent cloud software for contact centers in the United States, India, and internationally. It offers a virtual contact center cloud platform that delivers a suite of applications, which enables the breadth of contact center-related customer service, sales, and marketing functions. The company's platform comprises of including interactive virtual agent, agent assist, workflow automation, workforce engagement management, AI insights, and AI summaries that allows to manage and optimize customer interactions across voice, chat, email, web, social media, and mobile channels directly or through its application programming interfaces. It also matches each customer interaction with an agent resource and delivers customer data to the agent in real-time through integrations with adjacent enterprise applications, such as CRM software, to optimize the customer experience and enhance agent productivity. The company serves customers in various industries, such as banking and financial services, business process outsourcers, retail, healthcare, technology, and education. Five9, Inc. was incorporated in 2001 and is headquartered in San Ramon, California.

Norwegian Cruise Line stock logo

Norwegian Cruise Line NYSE:NCLH

$22.58 -0.57 (-2.46%)
Closing price 03:59 PM Eastern
Extended Trading
$22.60 +0.03 (+0.11%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Norwegian Cruise Line Holdings Ltd., together with its subsidiaries, operates as a cruise company in North America, Europe, the Asia-Pacific, and internationally. The company operates through the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands. It offers itineraries ranging from three days to a 180-days calling on various ports, including Scandinavia, Northern Europe, the Mediterranean, the Greek Isles, Alaska, Canada and New England, Hawaii, Asia, Tahiti and the South Pacific, Australia and New Zealand, Africa, India, South America, the Panama Canal, and the Caribbean. It distributes its products through retail/travel advisor and onboard cruise sales channels, as well as meetings, incentives, and charters. Norwegian Cruise Line Holdings Ltd. was founded in 1966 and is based in Miami, Florida.

Portola Pharmaceuticals stock logo

Portola Pharmaceuticals NASDAQ:PTLA

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$567.74 +7.98 (+1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$567.00 -0.74 (-0.13%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Tenet Healthcare stock logo

Tenet Healthcare NYSE:THC

$175.77 +2.11 (+1.22%)
As of 03:59 PM Eastern

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services, such as orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. It operates hospitals, ambulatory surgery centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.